Skip to content

State coverage

Connecticut

State Medicaid · 7 documents cited

Medicaid, for obesity: Covers with conditions. The conditions and the appeal deadline are in the summary below.

At a glance

Covers with conditions
Medicaid, for obesity
Gated the GLP-1s to diabetes, then added two cheap oral weight-loss drugs on the same day.
Appeal deadline
60 days from the decision, and it has to be mailed — the statute counts from when the decision was made, not from when you opened the envelope source
Primary source
Connecticut Medical Assistance Program, Provider Bulletin 2024-66, Policy Transmittal 2024-30
Date read
September 2026

Denise Ramirez, Coverage Editor · Who writes this site

Connecticut is usually listed among the states that pulled back on these drugs. What its own bulletins show is a swap rather than a retreat.

In December 2024 the state started requiring a type 2 diabetes diagnosis code on the pharmacy claim for the older GLP-1s — Ozempic, Mounjaro, Trulicity and the rest. If your prescriber was using one of them for weight, the claim stopped paying. That is the part that got reported.

The part that did not: on the same bulletin that extended the transition period, Connecticut added coverage of two weight-loss drugs it had never paid for. Orlistat and phentermine became covered for HUSKY A, B, C and D from July 1, 2025. They are the old, cheap, oral ones rather than the injectables, but they are covered for weight loss itself, which is more than most states on this site will do.

Alongside that, the state opened three named doors to the newer drugs for reasons other than obesity, each in its own dated bulletin. And underneath all of it sits a provider manual that still says the program does not pay for obesity drugs at all — a sentence the 2025 bulletins have overtaken.

What we could verify for Connecticut

The tightening came first, and it works at the pharmacy counter rather than through a prior authorization. From December 15, 2024, "all new prescriptions for GLP-1 agonist medications will require a valid ICD-10 diagnosis code indicating Type 2 diabetes to be submitted in field 424-DO on the NCPDP D.0. pharmacy claim." The bulletin names them: "Trulicity, Byetta, Bydureon, Rybelsus, Victoza/liraglutide, Ozempic, and Mounjaro (combination GIP and GLP-1)". Members already on one for another reason were given a transition period rather than an immediate stop.

Connecticut Medical Assistance Program, Provider Bulletin 2024-66, Policy Transmittal 2024-30, effective December 2024 · source

The same bulletin that extended that transition also opened a door nobody reported. Its subject line reads "Updated Diagnosis Requirement for GLP-1 Agonist Medications and New Coverage of FDA Approved Weight Loss Drug Phentermine and Orlistat", and the text is explicit: "Effective 7/1/2025, the Department of Social Service (DSS) will cover two FDA approved oral medications for weight loss through the pharmacy benefit for HUSKY A, B, C, and D" — orlistat and phentermine. Claims for members already on a GLP-1 for a non-diabetes reason were extended "through July 31, 2025."

Connecticut Medical Assistance Program, Provider Bulletin 2025-31, Policy Transmittal 2025-12, effective June 2025 · source

Wegovy got a cardiovascular door in early 2025: "Effective February 3, 2025, the Department will reimburse for new prescriptions for Wegovy through the pharmacy benefit when prescribed to reduce the risk of Major Adverse Cardiac Event (MACE) in adults 18 and older with established cardiovascular disease and either obesity or overweight", across HUSKY A, B, C and D. The bulletin warns that "Any PA form submitted without the required information will be denied."

Connecticut Medical Assistance Program, Provider Bulletin 2025-04, effective February 2025 · source

Zepbound got a sleep apnea door six months later: "Effective July 1, 2025, the Department will reimburse for new prescriptions for Zepbound through the pharmacy benefit when prescribed for the treatment of obstructive sleep apnea in adults 18 and older", again across HUSKY A, B, C and D.

Connecticut Medical Assistance Program, Provider Bulletin 2025-32, effective June 2025 · source

A liver door followed in the autumn, and it narrows the drug it opens. "Effective November 3, 2025, the Department will reimburse new prescriptions for Wegovy through the pharmacy benefit when prescribed to treat Metabolic-Associated Steatohepatitis (MASH) in adults 18 and older" — for HUSKY A, C and D, not B. The existing cardiovascular form stays available for people who already meet those criteria, and the same bulletin adds a diagnosis requirement for Wegovy.

Connecticut Medical Assistance Program, Provider Bulletin 2025-54, effective October 2025 · source

Connecticut's provider manual still says the opposite, and it is still the live document on the state's own portal. Chapter 7, under "III. Services Not Covered", lists what "The Department will not pay for" and item (b) is "Any drugs used in the treatment of obesity." Its cover is dated October 1, 2020 and its body pages carry a REVISED 05/01/03 stamp — so a reader who finds this chapter first will conclude the wrong thing about orlistat and phentermine, which the 2025 bulletin covers.

Connecticut Medical Assistance Program, Provider Manual Chapter 7 — Pharmacy Services Regulation/Policy, effective October 2020 · source

The filing window is in statute rather than in a bulletin, and it is measured from the decision: an application for a fair hearing "shall be mailed to the commissioner within sixty days after the rendition of such decision." The same section requires the commissioner to hold the hearing "within thirty days from receipt" of the application. The chapter is revised to January 1, 2026.

Connecticut General Statutes §17b-60, Fair hearings by commissioner, effective January 2026 · source

Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.

If the appeal fails, or you cannot wait

Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.

  • CoreAge RxAdvertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable.
  • OakFlat price across doses, free shipping with supplies.
  • Care Bare RxNames its pharmacies with addresses; sells brand Ozempic as well as compounded.
  • Gala HealthAll doses one price, but the advertised rate needs a yearly subscription.
  • Synergy RxProviders licensed in your state; publishes no GLP-1 price before the consult.
  • Breeze MedsServes all 50 states; publishes a starting price only.

Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.

Where this comes from

  1. Connecticut Medical Assistance Program, Provider Bulletin 2024-66, Policy Transmittal 2024-30, effective December 2024 — www.ctdssmap.com/CTPortal/Information/Get-Download-File?Filename=pb2024_
  2. Connecticut Medical Assistance Program, Provider Bulletin 2025-31, Policy Transmittal 2025-12, effective June 2025 — www.ctdssmap.com/CTPortal/Information/Get-Download-File?Filename=pb2025_
  3. Connecticut Medical Assistance Program, Provider Bulletin 2025-04, effective February 2025 — www.ctdssmap.com/CTPortal/Information/Get-Download-File?Filename=pb2025_
  4. Connecticut Medical Assistance Program, Provider Bulletin 2025-32, effective June 2025 — www.ctdssmap.com/CTPortal/Information/Get-Download-File?Filename=pb2025_
  5. Connecticut Medical Assistance Program, Provider Bulletin 2025-54, effective October 2025 — www.ctdssmap.com/CTPortal/Information/Get-Download-File?Filename=pb2025_
  6. Connecticut Medical Assistance Program, Provider Manual Chapter 7 — Pharmacy Services Regulation/Policy, effective October 2020 — www.ctdssmap.com/CTPortal/Information/Get-Download-File?Filename=ch7_pha
  7. Connecticut General Statutes §17b-60, Fair hearings by commissioner, effective January 2026 — www.cga.ct.gov/current/pub/chap_319q.htm

Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.